TR199902442T2 - Seker ve sismanlik tedavisinde 3 agonistleri olarak tiazol benzensülfonamidler. - Google Patents

Seker ve sismanlik tedavisinde 3 agonistleri olarak tiazol benzensülfonamidler.

Info

Publication number
TR199902442T2
TR199902442T2 TR1999/02442T TR9902442T TR199902442T2 TR 199902442 T2 TR199902442 T2 TR 199902442T2 TR 1999/02442 T TR1999/02442 T TR 1999/02442T TR 9902442 T TR9902442 T TR 9902442T TR 199902442 T2 TR199902442 T2 TR 199902442T2
Authority
TR
Turkey
Prior art keywords
treatment
compounds
agonists
swelling
levels
Prior art date
Application number
TR1999/02442T
Other languages
English (en)
Inventor
J. Mathvink Robert
R. Parmee Emma
Tolman Samuel
E. Weber Ann
Original Assignee
Merck & Co.,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9705041.3A external-priority patent/GB9705041D0/en
Application filed by Merck & Co.,Inc. filed Critical Merck & Co.,Inc.
Publication of TR199902442T2 publication Critical patent/TR199902442T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Tiazol konmus benzensülfonamidler, çok az 1 ve 2 adrenerjik reseptör aktivitesi ile 3 adrenerjik reseptör agonistleridir ve bilesikler hücrelerdeki lipolisisleri ve enerji harcanmasini artirirlar. Böylece bilesiklerin II. Tip diyabet ve sismanlik tedavisinde etkili bir aktivetesi vardir. Bilesikler ayrica trigliserid seviyesinin ve kolestrol seviyesinin düsürülmesinde veya yüksek yogunluktaki lipoprotein seviyesinin artirilmasi veya bagirsak hareketliginin azaltilmasinda kullanilabilirler. Bunlara ek olarak nörojenik iltihaplanmalarin azaltilmasi için veya antidepressant ajan olarak kullanilabilirler. Bilesik, aminoalkilfenil-sülfonamidin uygun bir sekilde epoksid ile çiftlestirilmesi ile hazirlanmistir. Diabetin ve sismanligin tedavisi ve trigliserid ve kolestrol seviyelerinin düsürülmesi veya yüksek yogunluktaki lipoprotein seviyesinin arttirilmasi veya bagirsak hareketliliginin azaltilmasi için yöntemler ve kompozisyonlar da verilmistir.
TR1999/02442T 1997-01-28 1998-01-23 Seker ve sismanlik tedavisinde 3 agonistleri olarak tiazol benzensülfonamidler. TR199902442T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3676097P 1997-01-28 1997-01-28
GBGB9705041.3A GB9705041D0 (en) 1997-03-12 1997-03-12 Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity

Publications (1)

Publication Number Publication Date
TR199902442T2 true TR199902442T2 (tr) 2000-07-21

Family

ID=26311166

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02442T TR199902442T2 (tr) 1997-01-28 1998-01-23 Seker ve sismanlik tedavisinde 3 agonistleri olarak tiazol benzensülfonamidler.

Country Status (22)

Country Link
EP (1) EP0968209A1 (tr)
JP (1) JP2001509166A (tr)
KR (1) KR20000070568A (tr)
CN (1) CN1251099A (tr)
AR (1) AR011092A1 (tr)
AU (1) AU728812B2 (tr)
BG (1) BG103686A (tr)
BR (1) BR9807096A (tr)
CA (1) CA2278739A1 (tr)
EA (1) EA199900692A1 (tr)
EE (1) EE9900328A (tr)
HR (1) HRP980044A2 (tr)
HU (1) HUP0002053A3 (tr)
ID (1) ID22273A (tr)
IL (1) IL131130A0 (tr)
IS (1) IS5131A (tr)
NO (1) NO993646L (tr)
PE (1) PE52299A1 (tr)
PL (1) PL334833A1 (tr)
SK (1) SK100099A3 (tr)
TR (1) TR199902442T2 (tr)
WO (1) WO1998032753A1 (tr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19824175A1 (de) * 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
EP1743655B1 (en) 2000-01-21 2014-06-25 Novartis AG Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
TR200401359T4 (tr) 2000-03-31 2004-08-23 Pfizer Products Inc. İkame edilmiş piridinlerin hazırlanmasına yönelik işlem
EP1303509B1 (en) 2000-07-13 2012-11-28 Eli Lilly And Company Beta3 adrenergic agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
WO2002038544A2 (en) 2000-11-10 2002-05-16 Eli Lilly And Company 3-substituted oxindole beta 3 agonists
CA2431171A1 (en) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
CA2450562A1 (en) * 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002318206A1 (en) 2001-08-14 2003-03-03 Jolie Anne Bastian 3-substituted oxindole beta-3 agonists
US7208505B2 (en) 2001-08-14 2007-04-24 Eli Lilly And Company β3 adrenergic agonists
JP2005507932A (ja) * 2001-10-12 2005-03-24 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのフェニル置換５−員窒素含有複素環
ATE297925T1 (de) 2001-11-20 2005-07-15 Lilly Co Eli 3-substituierte oxindol beta 3 agonisten
WO2003044017A1 (en) 2001-11-20 2003-05-30 Eli Lilly And Company Beta 3 adrenergic agonists
AU2002357084A1 (en) 2002-01-11 2003-07-30 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
WO2006132196A1 (ja) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β３作動薬を含有する新規な医薬
PT1931350E (pt) 2005-09-14 2014-02-12 Takeda Pharmaceutical Administração de inibidores de dipeptidil peptidase
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
ATE511842T1 (de) 2005-10-04 2011-06-15 Merck Sharp & Dohme Kombinationstherapie zur behandlung von erhöhter miktionsfrequenz, akutem harndrang und inkontinenz
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PL2531501T3 (pl) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
AU6038498A (en) 1998-08-18
JP2001509166A (ja) 2001-07-10
NO993646D0 (no) 1999-07-27
PL334833A1 (en) 2000-03-27
CA2278739A1 (en) 1998-07-30
HUP0002053A3 (en) 2001-09-28
IS5131A (is) 1999-07-23
CN1251099A (zh) 2000-04-19
HRP980044A2 (en) 1998-10-31
ID22273A (id) 1999-09-23
AU728812B2 (en) 2001-01-18
PE52299A1 (es) 1999-05-26
EA199900692A1 (ru) 2000-02-28
BR9807096A (pt) 2000-04-18
NO993646L (no) 1999-09-27
BG103686A (bg) 2000-06-30
IL131130A0 (en) 2001-01-28
AR011092A1 (es) 2000-08-02
KR20000070568A (ko) 2000-11-25
SK100099A3 (en) 2000-05-16
EP0968209A1 (en) 2000-01-05
WO1998032753A1 (en) 1998-07-30
HUP0002053A2 (hu) 2001-08-28
EE9900328A (et) 2000-02-15

Similar Documents

Publication Publication Date Title
TR199902442T2 (tr) Seker ve sismanlik tedavisinde 3 agonistleri olarak tiazol benzensülfonamidler.
ES2104259T3 (es) Fenilsulfonamidas sustituidas como agonistas beta3 selectivos para el tratamiento de la diabetes y la obesidad.
MXPA03000308A (es) Agonistas beta3 adrenergicos.
HUXTABLE et al. The effect of a pyrrolizidine alkaloid, monocrotaline, and a pyrrole, dehydroretronecine, on the biochemical functions of the pulmonary endothelium
WO2005097051A3 (en) Disulfide dyes, composition comprising them and method of dyeing hair
NO964548L (no) Substituerte sulfonamider som selektive 3 agonister for behandling av diabetes og fedme
ES2048560T3 (es) Fibra dietetica, su procedimiento y composicion con actividad fisiologica que lo contiene como ingrediente activo.
Ohmiya et al. Evidence that endo‐1, 4‐β‐glucanases act on cellulose in suspension‐cultured poplar cells
BRPI0408165A (pt) processos para melhorar a atividade das enzimas de degradação de lignocelulose
ATE260910T1 (de) 4-heteroaryl-tetrahydrochinoline und ihre verwendung als inhibitoren des cholesterin-ester- transfer-proteins (ctep)
TR199902552T2 (tr) Fungisidal triflorometilalkilamino-triazolopirimidinler.
DE60023660D1 (de) Antizymmodulatoren sowie deren verwendung
Mountfort The rumen anaerobic fungi
DE69412551D1 (de) Isolierung und Struktur von Spongistatin 5, 7, 8 und 9 und deren Verwendung als Antitumor-Mittel
KR870008025A (ko) 정상 인체 결장 세포로 부터 인체조직 푸라스미노겐 활성화인자
DK1218494T3 (da) Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler
Hsieh et al. Regulation of basal and luminal cell-specific cytokeratin expression in rat accessory sex organs. Evidence for a new class of androgen-repressed genes and insight into their pairwise control.
DE69116192D1 (de) Für die Polysaccharidhydrolyse aus einem lignozellulosehaltigen Substrat geeignete Enzymzusammensetzung, ihre Herstellung und Verwendung
Macris et al. Production and cross-synergistic action of cellulolytic enzymes from certain fungal mutants grown on cotton and straw
ES2111741T3 (es) Microorganismo cepa w, composicion enzimatica obtenible a partir de este, utilizacion del microorganismo y procedimiento para la hidrolisis particularmente de queratina.
Borgers et al. The development of alkaline phosphatase in trichinous muscle
Gupta et al. Acid and enzymatic hydrolysis mediated bioethanol production from biomass of a noxious weed‐Parthenium hysterophorus L
BR0011905A (pt) Processo para gerar células e tecidos imunocompatìveis usando-se técnicas de transferência nuclear
KR920702624A (ko) 혈액 또는 기타 세포외 체액중의 유해 성분을 제거하거나 이를 비활성화시키기 위한 조성물
Wagle et al. Uncovering Pre‐messenger RNA Splicing Mechanisms in Retinitis Pigmentosa